Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cyclic GMP-AMP synthase (cGAS), encoded by the MB21D1 gene, is a critical cytosolic pattern recognition receptor and nucleotidyltransferase enzyme that acts as a primary sensor of double-stranded DNA (dsDNA) in the cytoplasm. Upon binding to aberrant cytosolic DNA—which can originate from viral or bacterial pathogens, or from self-DNA leaked due to cellular damage, genomic instability, or mitochondrial dysfunction—cGAS catalyzes the synthesis of the second messenger cyclic GMP-AMP (cGAMP) from ATP and GTP. cGAMP subsequently binds to and activates the stimulator of interferon genes (STING) adaptor protein, triggering a signaling cascade that leads to the production of type I interferons and pro-inflammatory cytokines.
While this pathway is essential for host defense against infections and tumor surveillance, chronic or aberrant activation of cGAS by self-DNA is a major driver of autoimmune and autoinflammatory diseases, such as systemic lupus erythematosus (SLE), Aicardi-Goutières syndrome (AGS), and various age-related inflammatory and neurodegenerative disorders. Consequently, cGAS has emerged as a highly attractive therapeutic target. Small-molecule cGAS inhibitors, such as VENT-03 and IMSB301, are currently in clinical development to suppress pathologic type I interferon signaling and treat autoimmune and inflammatory conditions.
Inhibition of cyclic GMP-AMP (cGAMP) synthesis by blocking cGAS enzymatic activity
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cyclic GMP-AMP synthase (cGAS) (cGAS).